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Clinical PerspectiveWhat Is New?We identified a novel multidimensional urinary biomarker consisting of 96 peptide fragments and named it heart failure predictor.Heart failure predictor predicts progression from asymptomatic left ventricular dysfunction to overt heart failure and is more accurate than a research‐optimized N‐terminal pro b‐type natriuretic peptide assay.What Are the Clinical Implications?Heart failure predictor might serve as a tool to improve risk stratification, patient management, and understanding the pathophysiology of heart failure.

Introduction {#jah32395-sec-0008}
============

Left ventricular (LV) heart failure (HF) is a clinical syndrome caused by adverse LV structural or functional alterations resulting in impaired ventricular filling and/or ejection and thus in the disability of the heart to pump a sufficient amount of blood to meet the metabolic needs of the body.[1](#jah32395-bib-0001){ref-type="ref"}, [2](#jah32395-bib-0002){ref-type="ref"} HF represents an enormous public health and socioeconomic burden.[1](#jah32395-bib-0001){ref-type="ref"}, [2](#jah32395-bib-0002){ref-type="ref"} Because of etiological diversity, it is difficult to clearly identify all contributing factors in a clinical setting and to depict the complex pathophysiology by single biomarkers. Difficulties thus arise in diagnosis, risk stratification, and management of HF patients.[2](#jah32395-bib-0002){ref-type="ref"} A position paper of the American Heart Association supported research into proteomics as applied to cardiovascular health and disease.[3](#jah32395-bib-0003){ref-type="ref"} In line with this recommendation, we developed multidimensional proteomic biomarkers characterizing distinct molecular manifestations of LV dysfunction that may provide additional diagnostic and prognostic value and identify new targets of treatment. We already identified specific peptide biomarker patterns helping in the diagnosis of coronary artery disease,[4](#jah32395-bib-0004){ref-type="ref"} and asymptomatic LV diastolic[5](#jah32395-bib-0005){ref-type="ref"}, [6](#jah32395-bib-0006){ref-type="ref"}and systolic[7](#jah32395-bib-0007){ref-type="ref"} dysfunction. The present study aimed to extend the findings[5](#jah32395-bib-0005){ref-type="ref"}, [6](#jah32395-bib-0006){ref-type="ref"}, [7](#jah32395-bib-0007){ref-type="ref"} of these case--control[5](#jah32395-bib-0005){ref-type="ref"}, [7](#jah32395-bib-0007){ref-type="ref"} and cross‐sectional[6](#jah32395-bib-0006){ref-type="ref"} studies and to investigate whether the urinary proteomic signature might predict progression from asymptomatic LV dysfunction to overt symptomatic HF.

Methods {#jah32395-sec-0009}
=======

Study Participants {#jah32395-sec-0010}
------------------

For discovery of the urinary biomarkers, we investigated 95 patients enrolled in the GS (Generation Scotland: Scottish Family Health Study),[8](#jah32395-bib-0008){ref-type="ref"} who had either HF at baseline (n=57) or progressed to HF during follow‐up (n=38) and 192 sex‐ and age‐matched healthy controls selected from the same cohort. For validation, we studied 175 patients with asymptomatic diastolic LV dysfunction at baseline enrolled in the FLEMENGHO (Flemish Study on Environment, Genes and Health Outcomes[5](#jah32395-bib-0005){ref-type="ref"}, [6](#jah32395-bib-0006){ref-type="ref"}), of whom over a 4.8‐year period 17 developed HF during follow‐up. The diagnosis of HF was ascertained against the records held by general practitioners or hospitals in the catchment area of the FLEMENGHO study.[9](#jah32395-bib-0009){ref-type="ref"} Both GS (ethical approval registration number, 10/S1402/20) and FLEMENGHO (ML4804) complied with the Helsinki declaration for research in humans[10](#jah32395-bib-0010){ref-type="ref"} and received ethical approval. Permission for health record linkage in GS was obtained from the Privacy Advisory Committee of NHS National Services Scotland. The FLEMENGHO database is registered with the Belgian Privacy Commission ([www.privacycommission.be](http://www.privacycommission.be)). All participants gave informed written consent.

Definition of LV Dysfunction {#jah32395-sec-0011}
----------------------------

In the GS study,[8](#jah32395-bib-0008){ref-type="ref"} HF was an ICD‐coded admission to the hospital for symptomatic HF. In FLEMENGHO,[5](#jah32395-bib-0005){ref-type="ref"}, [6](#jah32395-bib-0006){ref-type="ref"} the diagnosis of subclinical LV diastolic dysfunction relied on echocardiography. To ascertain the absence of symptoms, participants completed the London School of Hygiene questionnaires on cardiovascular and respiratory symptoms.[11](#jah32395-bib-0011){ref-type="ref"} As described elsewhere,[12](#jah32395-bib-0012){ref-type="ref"} guideline‐driven echocardiographic criteria to stage patients with advanced diastolic LV dysfunction leave a large proportion of people unclassified in population studies. We therefore developed age‐specific criteria in a healthy reference sample drawn from FLEMENGHO[12](#jah32395-bib-0012){ref-type="ref"} and replicated these criteria in an independent European population study.[13](#jah32395-bib-0013){ref-type="ref"} Diastolic LV dysfunction included[12](#jah32395-bib-0012){ref-type="ref"}, [13](#jah32395-bib-0013){ref-type="ref"}: (1) patients with an abnormally low age‐specific transmitral E/A ratio indicative of impaired relaxation, but without evidence of increased LV filling pressures (E/e′ ≤8.5); (2) patients with a mildly‐to‐moderately elevated LV filling pressure (E/e′ \>8.5) and an E/A ratio within the normal age‐specific range; and (3) patients with an elevated E/e′ ratio and an abnormally low age‐specific E/A ratio (combined dysfunction).

Proteomic Urine Sample Analysis {#jah32395-sec-0012}
-------------------------------

### Sample preparation and capillary electrophoresis--mass spectrometry analysis {#jah32395-sec-0013}

For proteomic analysis, a 0.7‐mL aliquot of stored urine was thawed immediately before use and diluted with 0.7 mL of 2 mol/L urea, and 10 mmol/L NH~4~OH containing 0.02% sodium dodecyl sulphate. To remove higher molecular mass proteins, such as albumin and immunoglobulins, the sample was ultrafiltered using Centrisart ultracentrifugation filter devices (20 kDa MWCO; Sartorius, Göttingen, Germany) at 3000 relative centrifugal force units until 1.1 mL of filtrate was obtained. This filtrate was then applied onto a PD‐10 desalting column (GE Healthcare, Uppsala, Sweden) equilibrated in 0.01% NH~4~OH in HPLC‐grade in H~2~O (Carl Roth GmbH, Karlsruhe, Germany) to decrease matrix effects by removing urea, electrolytes, salts, and to enrich polypeptides. Finally, all samples were lyophilized, stored at 4°C, and suspended in HPLC‐grade H~2~O shortly before capillary electrophoresis--mass spectrometry (CE‐MS) analyses.[14](#jah32395-bib-0014){ref-type="ref"}

CE‐MS analyses were performed using a P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Fullerton, CA) on‐line coupled to a micrOTOF MS (Bruker Daltonics, Bremen, Germany).[14](#jah32395-bib-0014){ref-type="ref"}, [15](#jah32395-bib-0015){ref-type="ref"} The electrospray ionization device (Agilent Technologies, Palo Alto, CA) was grounded, and the ion spray interface potential was set between −4 and −4.5 kV. Data acquisition and MS acquisition methods were automatically controlled by the CE via contact‐close‐relays. Spectra were accumulated every 3 s, over a mass‐to‐charge ratio (m/z) ranging from 350 to 3000.

### Quality control {#jah32395-sec-0014}

Accuracy, precision, selectivity, sensitivity, reproducibility (Figure [1](#jah32395-fig-0001){ref-type="fig"}), and stability of the CE‐MS have been previously published.[14](#jah32395-bib-0014){ref-type="ref"}, [16](#jah32395-bib-0016){ref-type="ref"} Quality control involves daily CE‐MS runs of human urine standards.[16](#jah32395-bib-0016){ref-type="ref"} CE has a high reproducibility with at least 70% of peptide recovered compared with only 43% by liquid chromatography. To prevent variability because of carry‐over effects from 1 to the next run, capillaries are reconditioned between runs (eg, 1 mol/L NaOH). Figure [1](#jah32395-fig-0001){ref-type="fig"} shows proteome coverage of 6 CE‐MS runs of human urine standards. The coefficient of variance estimated from over 600 urine samples collected once daily for over 3 years was 5.8%.[17](#jah32395-bib-0017){ref-type="ref"}

![Proteome coverage of 6 CE‐MS runs (A through F) of human urine standards. The molecular mass on a logarithmic scale (0.8--20 kDa on the *y*‐axis) was plotted against the normalized CE migration time (15--45 minutes on the *x*‐axis). Peak height and color represent average signal intensity. The human urine standard is a urine sample from a randomly selected healthy person that is used for quality control.[16](#jah32395-bib-0016){ref-type="ref"} CE‐MS indicates capillary electrophoresis--mass spectrometry.](JAH3-6-e005432-g001){#jah32395-fig-0001}

### Mass spectrometric data processing {#jah32395-sec-0015}

Mass spectral peaks representing identical molecules at different charge states were deconvoluted into single masses, using MosaiquesVisu software.[18](#jah32395-bib-0018){ref-type="ref"} Only signals with z of more than 1 observed in a minimum of 3 consecutive spectra with a signal‐to‐noise ratio of at least 4 were considered. Reference signals of 1770 urinary polypeptides were used for CE‐time calibration by locally weighted regression. For normalization of analytical and urine dilution variances, signal intensities were normalized relative to 29 "housekeeping" peptides.[19](#jah32395-bib-0019){ref-type="ref"}, [20](#jah32395-bib-0020){ref-type="ref"} The obtained peak lists characterize each polypeptide by its molecular mass, normalized CE migration time, and normalized signal intensity. All detected peptides were deposited, matched, and annotated in a Microsoft SQL database, allowing further statistical analysis.[21](#jah32395-bib-0021){ref-type="ref"} For clustering, peptides in different samples were considered identical, if mass deviation was \<50 ppm. CE migration time was controlled to be below 0.35 minutes after calibration.

### Sequencing of polypeptides {#jah32395-sec-0016}

HF biomarkers were in silico assigned to the previously sequenced peptides from Human Urinary Proteome Database, version 2.0.[22](#jah32395-bib-0022){ref-type="ref"} Peptides from this database were sequenced, as described elsewhere.[23](#jah32395-bib-0023){ref-type="ref"}, [24](#jah32395-bib-0024){ref-type="ref"} Briefly, urinary peptides were fragmented using different tandem mass spectrometric techniques with a prior separation step with CE or HPLC. Fragmentation spectra were matched to the protein sequences from up‐to‐date public databases (IPI, NCBI Reference Sequence Database and Uniprot), using MS/MS search engines MASCOT (Matrix Sciences Ltd., London, UK) and OMSSA (National Center for Biotechnology Information, Bethesda, MD). In matching, we accounted for urinary proteins posttranslational modifications, such as hydroxylation of lysine and proline, and specific MS characteristics. Peptide sequences from liquid chromatography--MS analyses were verified by the comparison of experimental and theoretical CE migration time, which is dependent on the number of basic and neutral polar amino acids.

Identified HF‐specific urinary peptides were combined into a single multidimensional classifier called Heart Failure Predictor (HFP), using the support vector machine‐based MosaCluster software, version 1.7.0.[25](#jah32395-bib-0025){ref-type="ref"} MosaCluster calculates classification scores based on the amplitudes of the selected biomarkers. Classification is performed by determining the Euclidian distance (defined as the support‐vector machine classification score) of the vector to a maximal margin hyperplane. The parameters for derivation of the HFP classifier were 6.4 for C, 0.008192 for gamma, and 0.001 for epsilon. In sensitivity analyses, we forced sex and age into the computations of the classification scores.

Other Measurements {#jah32395-sec-0017}
------------------

Hypertension was a blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or use of antihypertensive drugs. Venous blood samples were drawn after at least 6 hours of fasting for measurement of plasma glucose and serum total and high‐density lipoprotein cholesterol and serum creatinine. We derived the estimated glomerular filtration rate from serum creatinine by the Modification of Diet in Renal Disease formula.[26](#jah32395-bib-0026){ref-type="ref"} Diabetes mellitus was a self‐reported diagnosis, a fasting glucose level of at least 7 mmol/L, or use of antidiabetic agents.[27](#jah32395-bib-0027){ref-type="ref"} In the GS study,[8](#jah32395-bib-0008){ref-type="ref"} N‐terminal proatrial natriuretic peptide (NT‐proBNP) was measured using an automated ELISA assay (Roche Diagnostics, Basel, Switzerland) with an interassay coefficient of variation of \<3%. The lower limit of detection was 5 pg of NT‐proBNP per mL. In the FLEMENGHO study,[12](#jah32395-bib-0012){ref-type="ref"}, [13](#jah32395-bib-0013){ref-type="ref"} NT‐proBNP was measured in plasma by a competitive enzyme immunoassay for research use (Biomedica Gruppe, Vienna, Austria).[28](#jah32395-bib-0028){ref-type="ref"} The interassay and intra‐assay variations were lower than 15%. The lower detection limit was 5 pmol of NT‐proBNP/L. The standard range provided by the manufacturer of the enzyme immunoassay is from 0 to 1000 pmol/L (median, 208 pmol/L; 95% percentile, 300 pmol/L).

Statistical Analysis {#jah32395-sec-0018}
--------------------

We compared means and proportions characterizing the study participants at baseline by Student *t* test and Fisher exact test, respectively. We compared urinary peptide levels with a detectable signal in at least 30% of participants by the nonparametric Wilcoxon rank sum test. Unadjusted *P* values were calculated using the normal approximation of the Wilcoxon test statistic. In the GS study, we applied the Benjamini‐Hochberg approach with the false discovery rate set at 5%.[29](#jah32395-bib-0029){ref-type="ref"} We used Cox regression to compute hazard ratios and to determine clinical characteristics relevant for progression to overt HF. We identified covariables to be retained by a backward elimination with the *P* value set at 0.1. Variables with physiological relevance that were not retained by the stepdown procedure were combined in a propensity score[30](#jah32395-bib-0030){ref-type="ref"} derived by regressing HFP on covariables, including sex, body mass index, mean arterial pressure, heart rate, LV mass index, treatment with inhibitors of the renin system, and use of β‐blockers. To account for the small sample size in the replication sample (FLEMENGHO[5](#jah32395-bib-0005){ref-type="ref"}, [6](#jah32395-bib-0006){ref-type="ref"}), we applied Firth regression.[31](#jah32395-bib-0031){ref-type="ref"} In FLEMENGHO participants,[5](#jah32395-bib-0005){ref-type="ref"}, [6](#jah32395-bib-0006){ref-type="ref"} we evaluated the discriminatory performance of HFP by constructing the receiver operating characteristic curve and calculating the area under the receiver operating characteristic curve.

Results {#jah32395-sec-0019}
=======

Design of HFP in the GS Study {#jah32395-sec-0020}
-----------------------------

Cases were 57 patients with overt HF (ICD10 code, I50.1) present at baseline and 38 patients who over a 5‐year follow‐up period progressed to symptomatic HF requiring hospitalization (median time to event, 2.9 years). Among cases with incident HF, 19 (50%) had elevated levels of NT‐proBNP (\>125 pg/mL) at baseline. Controls were 192 sex‐ and age‐matched healthy individuals with normal NT‐proBNP level (Table [1](#jah32395-tbl-0001){ref-type="table-wrap"}).

###### 

Baseline Characteristics of Cases and Controls Nested in the GS

  Characteristic                 HF at Baseline                                         Incident HF                                            Healthy Controls
  ------------------------------ ------------------------------------------------------ ------------------------------------------------------ ------------------
  Number                         57                                                     38                                                     192
  Number of subjects, %                                                                                                                        
  Women                          18 (31.6)                                              12 (31.6)                                              61 (31.3)
  Hypertension                   46 (80.7)                                              26 (68.6)                                              157 (81.8)
  Diabetes mellitus              9 (15.8)                                               3 (7.9)                                                8 (4.2)
  Obesity                        23 (41.1)                                              10 (26.3)                                              42 (22.0)
  Mean (SD) of characteristic                                                                                                                  
  Age, y                         69±10[a](#jah32395-note-0002){ref-type="fn"}           64±11                                                  64±9
  Body mass index, kg/m^2^       29±5[a](#jah32395-note-0002){ref-type="fn"}            28±5                                                   27±5
  Waist‐to‐hip ratio             0.94±0.08[a](#jah32395-note-0002){ref-type="fn"}       0.91±0.07                                              0.91±0.09
  Blood pressure, mm Hg                                                                                                                        
  Systolic pressure              136±23                                                 143±21                                                 141±17
  Diastolic pressure             78±13[a](#jah32395-note-0002){ref-type="fn"}           81±12[a](#jah32395-note-0002){ref-type="fn"}           82±10
  Heart rate, beats per minute   68±12                                                  70±14                                                  67±11
  Biochemical data                                                                                                                             
  Serum creatinine, μmol/L       94±28[a](#jah32395-note-0002){ref-type="fn"}           85±19[a](#jah32395-note-0002){ref-type="fn"}           80±13
  eGFR, mL/min per 1.73 m^2^     74±22[a](#jah32395-note-0002){ref-type="fn"}           80±17[a](#jah32395-note-0002){ref-type="fn"}           85±15
  Total cholesterol, mmol/L      4.3±1.0[a](#jah32395-note-0002){ref-type="fn"}         4.9±1.4[a](#jah32395-note-0002){ref-type="fn"}         5.2±1.1
  HDL cholesterol, mmol/L        1.2±0.4[a](#jah32395-note-0002){ref-type="fn"}         1.3±0.4[a](#jah32395-note-0002){ref-type="fn"}         1.4±0.4
  Plasma glucose, mmol/L         5.8±2.2[a](#jah32395-note-0002){ref-type="fn"}         5.2±1.6[a](#jah32395-note-0002){ref-type="fn"}         5.1±1.3
  NT‐proBNP, pg/mL               278 (93--774)[a](#jah32395-note-0002){ref-type="fn"}   132 (69--242)[a](#jah32395-note-0002){ref-type="fn"}   48 (32--72)

Values are mean (±SD) or geometric mean (interquartile range). Hypertension was an office blood pressure of ≥140 mm Hg systolic, ≥90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a self‐reported diagnosis, a fasting glucose level of at least 7 mmol/L, or use of antidiabetic agents. Obesity was a body mass index of ≥30 kg/m^2^. For NT‐proBNP, values are geometric mean (interquartile range). eGFR indicates estimated glomerular filtration rate; HDL, high‐density lipoprotein; HF, heart failure; NT‐proBNP, N‐terminal pro‐b‐type natriuretic peptide.

Indicates a difference (*P*≤0.05) between cases and controls.

Impaired renal function is a potential confounder in urinary biomarker discovery.[32](#jah32395-bib-0032){ref-type="ref"} We therefore excluded the 10 patients with an estimated glomerular filtration rate of \<45 mL/min per 1.73 m^2^ (stage 3B according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guideline \[[www.kidney.org](http://www.kidney.org)\]) from biomarker discovery, leaving 49 with overt HF at baseline and 36 with incident HF. The total number of detected peptide fragments was 5616, but only 1380 (24.6%) with a signal in at least 30% of study participants were analyzed. Of these 1380 peptides (Figure [2](#jah32395-fig-0002){ref-type="fig"}), 722 were not sequenced and 658 were sequenced. The sequenced peptides enabled identification of 157 parent proteins. Comparison of cases and controls with the false discovery rate set at 5% identified 96 potential peptide biomarkers, of which 59 were characterized by sequence and posttranslational modification (Table [2](#jah32395-tbl-0002){ref-type="table-wrap"}). The majority of the sequenced peptides originated from the extracellular matrix and were fragments of collagen I (n=33), III (n=10), as well as collagen IV, VII, and IX (each n=1). Other peptides originated from α‐1‐antitrypsin, fibrinogen α (n=2), kininogen‐1, microtubule‐associated protein τ, osteopontin (n=2), plasma protease C1 inhibitor, and serum albumin (Table [2](#jah32395-tbl-0002){ref-type="table-wrap"}).

![Flow chart illustrating the peptides retained in the generation of HFP. HFP indicates Heart Failure Predictor.](JAH3-6-e005432-g002){#jah32395-fig-0002}

###### 

Sequenced Peptides Included in the Heart Failure‐Specific Peptide Panel in the GS Cohort

  ID       Sequence                            Protein Name                                      Accession Number        BAS     INC     Overlap
  -------- ----------------------------------- ------------------------------------------------- ----------------------- ------- ------- ---------
  107929   DAaHKSEVAHRFKDLGEENFKALVL           Serum albumin                                     [P02768](P02768)        +28.1   +44.5   
  2505     SpGEAGRpG                           Collagen α‐1(I) chain                             [P02452](P02452)        −2.2    −1.3    2
  2659     DDGEAGKpG                           Collagen α‐1(I) chain                             [P02452](P02452)        −2.1    −1.2    2
  5675     DGKTGPpGPA                          Collagen α‐1(I) chain                             [P02452](P02452)        −2.1    −1.2    
  14906    DGRpGPpGPpG                         Collagen α‐1(I) chain                             [P02452](P02452)        −2.7    −1.4    2
  16779    ApGDRGEpGPP                         Collagen α‐1(I) chain                             [P02452](P02452)        −2.8    +1.3    
  17694    ApGDRGEpGpP                         Collagen α‐1(I) chain                             [P02452](P02452)        −2.8    −1.3    2
  21365    PpGEAGKpGEQG                        Collagen α‐1(I) chain                             [P02452](P02452)        +1.8    −1.0    2
  23697    DDGEAGKpGRpG                        Collagen α‐1(I) chain                             [P02452](P02452)        −2.1    −1.2    1
  28561    SpGPDGKTGPpGPA                      Collagen α‐1(I) chain                             [P02452](P02452)        −2.9    −1.5    1,2
  30575    SpGSpGPDGKTGPp                      Collagen α‐1(I) chain                             [P02452](P02452)        −3.3    −1.2    
  32171    ApGDRGEpGPpGPA                      Collagen α‐1(I) chain                             [P02452](P02452)        −1.5    −1.2    1,2
  35339    ApGDRGEpGPpGPAG                     Collagen α‐1(I) chain                             [P02452](P02452)        −1.4    −1.1    1,2
  42594    VGPpGpPGPPGPPGPPS                   Collagen α‐1(I) chain                             [P02452](P02452)        −1.8    −1.2    
  43442    VGPpGPpGPpGPPGPPS                   Collagen α‐1(I) chain                             [P02452](P02452)        −1.4    −1.1    
  50638    PpGPpGKNGDDGEAGKP                   Collagen α‐1(I) chain                             [P02452](P02452)        −2.1    +1.1    
  51175    EGSpGRDGSpGAKGDRG                   Collagen α‐1(I) chain                             [P02452](P02452)        −2.3    +1.1    
  51875    VGPpGPpGPpGPPGPPSAG                 Collagen α‐1(I) chain                             [P02452](P02452)        +1.6    +1.1    
  62504    TGPIGPpGPAGApGDKGESGP               Collagen α‐1(I) chain                             [P02452](P02452)        +2.1    +1.2    
  63209    EGSpGRDGSpGAKGDRGET                 Collagen α‐1(I) chain                             [P02452](P02452)        −2.0    −1.1    2
  65257    SGEpGApGSKGDTGAKGEpGP               Collagen α‐1(I) chain                             [P02452](P02452)        +1.7    +3.2    2
  72896    SGEpGApGSKGDTGAKGEpGPVG             Collagen α‐1(I) chain                             [P02452](P02452)        +1.2    +1.4    
  75846    GPpGEAGKpGEQGVpGDLGApGP             Collagen α‐1(I) chain                             [P02452](P02452)        +1.2    +1.3    
  77018    DGQPGAKGEpGDAGAKGDAGPPGp            Collagen α‐1(I) chain                             [P02452](P02452)        +1.2    +1.4    
  78073    AEGSpGRDGSpGAKGDRGETGPA             Collagen α‐1(I) chain                             [P02452](P02452)        −1.1    −2.1    
  81457    IGPpGPAGApGDKGESGPSGPAGPTG          Collagen α‐1(I) chain                             [P02452](P02452)        −1.1    −1.8    
  82234    IGPpGPAGApGDkGESGPSGPAGPTG          Collagen α‐1(I) chain                             [P02452](P02452)        −1.2    −2.6    
  87460    KGNSGEPGApGSKGDTGAKGEPGPVG          Collagen α‐1(I) chain                             [P02452](P02452)        +1.5    +1.9    
  99808    LTGPIGPPGpAGApGDKGESGPSGPAGPTG      Collagen α‐1(I) chain                             [P02452](P02452)        −1.2    −1.2    
  118163   LTGSpGSpGpDGKTGPPGPAGQDGRPGPpGppG   Collagen α‐1(I) chain                             [P02452](P02452)        −1.1    −1.5    
  36769    DGPpGRDGQpGHKG                      Collagen α‐2(I) chain                             [P08123](P08123)        −1.2    −2.1    
  48093    GpAGPRGERGPpGESGA                   Collagen α‐2(I) chain                             [P08123](P08123)        +1.2    +2.0    2
  110240   LKGQpGApGVKGEpGApGENGTPGQTGARG      Collagen α‐2(I) chain                             [P08123](P08123)        +7.7    +2.2    
  114086   TGEVGAVGPpGFAGEKGPSGEAGTAGPpGTpGP   Collagen α‐2(I) chain                             [P08123](P08123)        +1.3    +2.0    
  18988    DGESGRpGRpG                         Collagen α‐1(III) chain                           [P02461](P02461)        −1.2    −3.0    
  28747    SpGERGETGPpGP                       Collagen α‐1(III) chain                           [P02461](P02461)        +1.1    +1.4    1
  30699    DGApGKNGERGGpG                      Collagen α‐1(III) chain                           [P02461](P02461)        −1.0    −2.4    2
  36784    DGVPGKDGPRGPTGP                     Collagen α‐1(III) chain                           [P02461](P02461)        +1.0    +2.0    2
  38798    GLpGTGGPpGENGKpG                    Collagen α‐1(III) chain                           [P02461](P02461)        −1.1    −2.1    2
  49295    ApGGKGDAGApGERGPpG                  Collagen α‐1(III) chain                           [P02461](P02461)        +1.2    +1.8    
  61304    GLpGTGGPpGENGKPGEPGp                Collagen α‐1(III) chain                           [P02461](P02461)        +1.5    +3.6    2
  61945    GLpGTGGPpGENGKpGEPGp                Collagen α‐1(III) chain                           [P02461](P02461)        +1.6    +2.6    2
  64887    GApGApGGKGDAGApGERGPpG              Collagen α‐1(III) chain                           [P02461](P02461)        +1.3    +2.4    
  107460   KNGETGPQGPPGPTGPGGDKGDTGPpGpQG      Collagen α‐1(III) chain                           [P02461](P02461)        −1.2    −1.7    1
  84484    pGFPGAQGEPGSQGEpGDpGLpGP            Collagen α‐2(IV) chain                            [P08572](P08572)        +1.6    +2.8    
  30500    GApGLAGpAGpQGpS                     Collagen α‐1(VII) chain                           [Q02388--2](Q02388–2)   +1.7    +2.1    
  86029    PpGppGPpGVPGSDGIDGDNGPPGK           Collagen α‐2(IX) chain                            [H0Y409](H0Y409)        +1.3    +2.0    
  129940   DVGSYQEKVDVVLGPIQLQTPPRREEEPR       Deleted in malignant brain tumors 1 protein       [Q9UGM3](Q9UGM3)        +1.4    +2.0    
  98089    DEAGSEADHEGTHSTKRGHAKSRP            Fibrinogen α chain                                [P02671](P02671)        +1.6    +2.4    1
  103912   DEAGSEADHEGTHSTKRGHAKSRPV           Fibrinogen α chain                                [P02671](P02671)        +1.4    +1.9    
  17968    DGGGSPKGDVDP                        Sodium/potassium--transporting ATPase subunit γ   [P54710](P54710)        −1.2    −1.4    2
  13747    ATKTVGSDTF                          Kininogen‐1                                       [P01042--2](P01042–2)   +1.1    −2.8    
  67263    GSGGSSYGSGGGSYGSGGGGGGGRG           Keratin; type II cytoskeletal 1                   [P04264](P04264)        −1.1    −1.6    
  59368    FGASAGTGDLSDNHDIIS                  Vesicular integral--membrane protein VIP36        [Q12907](Q12907)        +1.7    +3.0    
  73434    KDQGGYTmHQDQEGDTDAG                 Microtubule--associated protein τ; MAPT           [P10636](P10636)        −1.3    −1.7    1
  87692    EDPQGDAAQKTDTSHHDQDHP               Short peptide from AAT                            [G3V387](G3V387)        −1.3    −2.1    
  73015    ELTETGVEAAAASAISVARTL               Plasma protease C1 inhibitor                      [P05155](P05155)        +1.9    +5.7    
  111426   IPVKQADSGSSEEKQLYNKYPDAVAT          Osteopontin                                       [P10451](P10451)        +1.9    +1.5    
  118694   IPVKQADSGSSEEKQLYNKYPDAVATW         Osteopontin                                       [P10451](P10451)        +2.9    +7.1    

The analysis of 49 cases with HF at baseline (BAS), 36 cases with incident HF (INC), and 192 controls identified 59 differentially excreted peptides that could be sequenced. The accession number is the identifier in the UniProtKB database ([www.uniprot.org](http://www.uniprot.org)). BAS and INC are fold changes of amplitude comparing heart failure cases at baseline (BAS) and incident heart failure at follow‐up (INC) to normal controls, respectively. The differential excretion was computed as (amplitude cases×frequency)/(amplitude control×frequency) or as (amplitude controls×frequency)/(amplitude cases×frequency) for upregulated (+) and downregulated (−) proteins in cases vs controls, respectively. Amplitude refers to the average mass spectrometric signal and frequency to the number of individuals with a detectable signal. Overlap refers to the peptide fragments also included in the previously published HF1 (1; reference [5](#jah32395-bib-0005){ref-type="ref"}) and HF patients with reduced ejection fraction (2; reference [7](#jah32395-bib-0007){ref-type="ref"}) classifiers. HF indicates heart failure.

To reduce overfitting in the support vector machine modeling, for the generation of a novel multidimensional classifier for HF, we included all available 95 cases, irrespective of their renal function. The resulting classifier, HFP (threshold level −0.22), allowed correct discrimination of 57 patients with HF at baseline and 38 patients with incident HF versus 192 controls with 100% accuracy upon complete take‐1‐out cross‐validation. HFP had 11 (11.5%) peptide fragments in common with the earlier published classifiers HF1 developed in hypertensive patients with asymptomatic LV diastolic dysfunction[5](#jah32395-bib-0005){ref-type="ref"}, [6](#jah32395-bib-0006){ref-type="ref"} and shared 22 (22.9%) peptides with HFrEF103 derived in HF patients with reduced ejection fraction.[7](#jah32395-bib-0007){ref-type="ref"} Twenty‐two of these common peptides have a known sequence (Table [2](#jah32395-tbl-0002){ref-type="table-wrap"}). Forcing sex and age into the computations of the classification scores did not affect the performance of HFP.

Replication of HFP in the FLEMENGHO Study {#jah32395-sec-0021}
-----------------------------------------

The prognostic utility of HFP was assessed in the independent FLEMENGHO cohort by applying the classifier onto the proteome profiles of 175 individuals with asymptomatic LV diastolic dysfunction but without previous coronary events (Table [3](#jah32395-tbl-0003){ref-type="table-wrap"}). Median follow‐up was 4.7 years (interquartile range, 4.5--5.1; range, 1.1--8.4 years) in 158 patients who did not progress to HF and 5.0 years (interquartile range, 4.4--6.2; range, 3.4--7.2) in 17 patients who developed overt diastolic HF (*P*=0.20). In stepdown Cox regression, age was the only covariable retaining significance. With adjustment for age and the propensity score, the hazard ratio for HF associated with HFP in Firth regression was 1.64 (CI, 1.05--2.53; *P*=0.029) for a 1‐SD increment. The corresponding hazard ratio for logarithmically transformed NT‐proBNP was 0.70 (CI, 0.36--1.38; *P*=0.31). In similarly adjusted models including both biomarkers, the hazard ratios were 1.63 (CI, 1.04--2.55; *P*=0.032) for HFP and 0.70 (CI, 0.35--1.41; *P*=0.32) for NT‐proBNP.

###### 

Baseline Characteristics of Cases and Controls in the FLEMENGHO Study

  Characteristic                 Cases                                          Controls
  ------------------------------ ---------------------------------------------- ----------------
  Number                         17                                             158
  Number of subjects, %                                                         
  Women                          11 (64.7)                                      90 (57.0)
  Hypertension                   13 (76.5)                                      128 (81.0)
  Diabetes mellitus              3 (17.7)                                       13 (8.2)
  Obesity                        4 (23.5)                                       52 (32.9)
  Mean (SD) of characteristic                                                   
  Age, y                         72±6[a](#jah32395-note-0005){ref-type="fn"}    64±13
  Body mass index, kg/m^2^       28±4                                           28±4
  Waist‐to‐hip ratio             0.89±0.08                                      0.90±0.08
  Blood pressure, mm Hg                                                         
  Systolic pressure              142±19                                         143±19
  Diastolic pressure             76±9[a](#jah32395-note-0005){ref-type="fn"}    82±10
  Heart rate, beats per minute   55±11[a](#jah32395-note-0005){ref-type="fn"}   63±11
  Biochemical data                                                              
  Serum creatinine, μmol/L       85±19                                          87±21
  eGFR, mL/min per 1.73 m^2^     71±16                                          72±14
  Total cholesterol, mmol/L      5.4±0.8                                        5.5±1.0
  HDL cholesterol, mmol/L        1.5±0.3                                        1.4±0.3
  Plasma glucose, mmol/L         5.6±1.9                                        5.2±1.1
  NT‐proBNP, pmol/L              269 (251--432)                                 245 (166--389)
  Echocardiography data                                                         
  LVEF, %                        68±9                                           70±9
  e′ peak, cm/s                  7.5±1.7                                        7.7±1.9
  E/e′                           9.9±2.6                                        9.2±2.9

Values are mean (±SD) or geometric mean (interquartile range). Hypertension was an office blood pressure of ≥140 mm Hg systolic, ≥90 mm Hg diastolic, or use of antihypertensive drugs. Diabetes mellitus was a self‐reported diagnosis, a fasting glucose level of at least 7 mmol/L, or use of antidiabetic agents. Obesity was a body mass index of ≥30 kg/m^2^. For NT‐proBNP, values are geometric mean (interquartile range). eGFR indicates estimated glomerular filtration rate; FLEMENGHO, Flemish Study on Environment, Genes and Health Outcomes; HDL, high‐density lipoprotein; HF, heart failure; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐b‐type natriuretic peptide.

Indicates a difference (*P*≤0.05) between cases and controls.

The area under the receiver operating characteristic curve for NT‐proBNP was 0.57 (95% CI, 0.42--0.72; *P*=0.62). For HFP, the area under the receiver operating characteristic curve was 0.70 (CI, 0.56--0.82; *P*=0.0047; Figure [3](#jah32395-fig-0003){ref-type="fig"}). The performance of the classifier made up of only type I collagens fragments (n=33) generated an area under the receiver operating characteristic curve of 0.60 (CI, 0.44--0.76; *P*=0.21).

![Receiver operating characteristic curve for the HFP score factors and NT‐proBNP values of the comparison between patients with preclinical left ventricular diastolic dysfunction who did and did not progress to overt heart failure in the FLEMENGHO cohort. FLEMENGHO indicates the Flemish Study on Environment, Genes and Health Outcomes; HFP, Heart Failure Predictor; NT‐proBNP, N‐terminal pro b‐type natriuretic peptide.](JAH3-6-e005432-g003){#jah32395-fig-0003}

Discussion {#jah32395-sec-0022}
==========

We identified urinary peptide biomarkers with prognostic value for the progression from asymptomatic LV dysfunction to overt HF. The ensuing multidimensional classifier HFP surpassed a research‐optimized NT‐proBNP assay in the prediction of progression to symptomatic HF. NT‐ProBNP, an inactive fragment of the cleaved pro‐BNP molecule, is the guideline‐endorsed state‐of‐the‐art clinical marker to confirm HF diagnosis.[33](#jah32395-bib-0033){ref-type="ref"}

From a mechanistic point of view, HFP extensively depicts specific excretory molecular phenotypic alterations associated with progressive LV dysfunction. Fragments of fibrillar type I and III collagen, important components of the myocardial extracellular matrix,[34](#jah32395-bib-0034){ref-type="ref"} predominantly make up the proteomic urinary signature associated with HF. These observations are in line with altered collagen synthesis,[35](#jah32395-bib-0035){ref-type="ref"} chemical/enzymatic cross‐linking,[36](#jah32395-bib-0036){ref-type="ref"} and/or turnover by different proteases[35](#jah32395-bib-0035){ref-type="ref"}, [37](#jah32395-bib-0037){ref-type="ref"} as the mechanisms underlying the perturbed LV mechanics and geometry[38](#jah32395-bib-0038){ref-type="ref"}, [39](#jah32395-bib-0039){ref-type="ref"} and progression to HF.[40](#jah32395-bib-0040){ref-type="ref"} Renal dysfunction secondary to HF[32](#jah32395-bib-0032){ref-type="ref"} might also have contributed to the urinary peptide excretion pattern as captured by HFP.

In addition to collagens, the biomarker pattern included peptide fragments from α‐1‐antitrypsin and osteopontin, which showed an elevated differential excretion in cases (Table [2](#jah32395-tbl-0002){ref-type="table-wrap"}). Levels of α‐1‐antitrypsin progressively increase across the New York Heart Association classes of HF and correlate with B‐type natriuretic peptide.[41](#jah32395-bib-0041){ref-type="ref"} This might be a compensatory mechanism for the loss of anti‐protease activity as a consequence of oxidative stress. The presence of a kininogen‐1 fragment in HFP indicated that alterations in kininogen‐1 and therefore kinins, its cleavage products, may also be relevant for the diagnosis and prediction of HF. Kinins, such as bradykinin (kallidin‐I) and lysyl‐bradykinin (kallidin‐II), are potent vasoactive and inflammatory peptides acting through the formation of nitric oxide radicals and prostacyclin.[42](#jah32395-bib-0042){ref-type="ref"} Inhibition of kinin degradation by angiotensin‐converting enzyme inhibitors increases LV ejection fraction and decreases the LV end‐diastolic volume,[43](#jah32395-bib-0043){ref-type="ref"} thereby underscoring the relevance of kinins in the pathophysiology of HF. Moreover, in line with the observed increased HF‐related excretion of osteopontin and altered excretion of collagen type I and III, López and coworkers demonstrated that elevated expression of osteopontin in HF patients correlated with collagen cross‐linking lysyl oxidase and insoluble collagen.[44](#jah32395-bib-0044){ref-type="ref"} Combined with NT‐proBNP, osteopontin improves the diagnosis of acute heart failure and refines risk stratification.[45](#jah32395-bib-0045){ref-type="ref"}

Conclusions {#jah32395-sec-0023}
===========

HFP is a novel biomarker derived from the urinary proteome and might serve as a tool to improve risk stratification, patient management, and understanding of the pathophysiology of HF. While the prognostic utility of HFP has been validated in a fully independent cohort, our study must be interpreted within the context of its limitations. First, the number of patients progressing to overt HF in the validation cohort was relatively small (9.7%), thus limiting the statistical assessment of the prognostic utility. However, we applied Firth regression as a bias‐corrected approach to conventional Cox regression. Second, we derived HFP from peptides with a detectable signal in at least 30% of study participants. Incomplete data might be perceived as a weakness. However, ignoring biomarkers with missing values wastes potentially important information, explaining why in proteomic studies missing values of 50% or more are commonly accepted without consensus about the threshold to be applied. Moreover, the 30% threshold in this article is in keeping with our previously published peer‐reviewed research. Third, the fact that not all identified polypeptides were sequenced impedes to some extent the insight into the pathophysiological mechanisms underlying HF. Finally, our current study cannot prove the origin of the urinary collagen fragments. However, we are now running proteomics on biopsies taken from explanted (diseased) and implanted (healthy) hearts during cardiac transplantation surgery in an attempt to prove that the urinary and tissue proteomic signatures are similar (<http://erc.europa.eu/projects-and-results/erc-funded-projects/prophet>). In spite of these limitations, our study underscores the diagnostic and prognostic power of a multidimensional biomarker approach. Further studies are necessary to reach the high level of evidence sufficient to establish HFP as a clinically valuable test.
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